iCAD (ICAD) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	ICAD INC
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		25,109,380
Entity Tax Identification Number	02-0377419
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Address, City or Town	Nashua
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 35,805	$ 27,186
Trade accounts receivable, net of allowance for doubtful accounts of $87 in 2021 and $111 in 2020	11,792	10,027
Inventory, net	3,290	3,144
Prepaid expenses and other current assets	1,989	1,945
Total current assets	52,876	42,302
Property and equipment, net of accumulated depreciation of $7,020 in 2021 and $6,778 in 2020	925	744
Operating lease assets	1,176	1,758
Other assets	1,657	1,527
Intangible assets, net of accumulated amortization of $8,667 in 2021 and $8,494 in 2020	741	889
Goodwill	8,362	8,362
Total assets	65,737	55,582
Current liabilities:
Accounts payable	2,651	2,869
Accrued and other expenses	5,523	7,039
Lease payable—current portion	856	726
Deferred revenue	5,930	6,117
Total current liabilities	14,960	16,751
Lease payable, long-term portion	431	1,075
Notes payable, long-term portion		6,960
Deferred revenue, long-term portion	520	267
Deferred tax	5	4
Total liabilities	15,916	25,057
Commitments and Contingencies
Stockholders' equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,287,837 as of September 30, 2021 and 23,693,735 as of December 31, 2020 Outstanding 25,102,006 as of September 30, 2021 and 23,508,575 as of December 31, 2020.	253	236
Additional paid-in capital	300,017	273,639
Accumulated deficit	(249,034)	(241,935)
Treasury stock at cost, 185,831 shares in 2021 and 2020	(1,415)	(1,415)
Total stockholders' equity	49,821	30,525
Total liabilities and stockholders' equity	$ 65,737	$ 55,582

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 87	$ 111
Property and equipment, accumulated depreciation and amortization	7,020	6,778
Intangible assets, accumulated amortization	$ 8,667	$ 8,494
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	25,287,837	23,693,735
Common stock, shares outstanding	25,102,006	23,508,575
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 9,361	$ 7,129	$ 25,830	$ 19,247
Cost of revenue:
Amortization and depreciation	79	92	237	287
Total cost of revenue	2,649	2,104	7,291	5,355
Gross profit	6,712	5,025	18,539	13,892
Operating expenses:
Engineering and product development	2,285	1,849	6,745	5,938
Marketing and sales	3,886	2,979	10,739	9,218
General and administrative	2,658	1,834	7,461	6,476
Amortization and depreciation	64	52	178	153
Total operating expenses	8,893	6,714	25,123	21,785
Loss from operations	(2,181)	(1,689)	(6,584)	(7,893)
Interest expense	0	(115)	(141)	(360)
Other income	5	10	12	85
Loss on extinguishment of debt	0		(386)	(341)
Loss on fair value of convertible debentures				(7,464)
Other income (expense), net	5	(105)	(515)	(8,080)
Loss before income tax expense	(2,176)	(1,794)	(7,099)	(15,973)
Tax expense	0	(3)	0	(34)
Net loss and comprehensive loss	$ (2,176)	$ (1,797)	$ (7,099)	$ (16,007)
Net loss per share:
Basic	$ (0.09)	$ (0.08)	$ (0.29)	$ (0.73)
Diluted	$ (0.09)	$ (0.08)	$ (0.29)	$ (0.73)
Weighted average number of shares used in computing loss per share:
Basic	25,053	23,173	24,662	21,827
Diluted	25,053	23,173	24,662	21,827
Product [Member]
Revenue:
Total revenue	$ 6,320	$ 4,538	$ 16,429	$ 11,220
Cost of revenue:
Total cost of revenue	1,807	1,345	4,592	2,899
Service [Member]
Revenue:
Total revenue	3,041	2,591	9,401	8,027
Cost of revenue:
Total cost of revenue	$ 763	$ 667	$ 2,462	$ 2,169

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flow from operating activities:
Net loss	$ (7,099)	$ (16,007)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	176	234
Depreciation	242	206
Bad debt provision	(25)	80
Stock-based compensation	2,102	2,542
Amortization of debt discount and debt costs	17	65
Loss on extinguishment of debt	386	341
Deferred tax expense		1
Change in fair value of convertible debentures		7,464
Changes in operating assets and liabilities:
Accounts receivable	(1,827)	1,151
Inventory	(146)	(535)
Prepaid and other assets	493	69
Accounts payable	(217)	96
Accrued expenses	(2,028)	(2,322)
Deferred revenue	65	532
Total adjustments	(762)	9,924
Net cash used for operating activities	(7,861)	(6,083)
Cash flow from investing activities:
Additions to patents, technology and other	(24)	(11)
Additions to property and equipment	(426)	(275)
Net cash used for investing activities	(450)	(286)
Cash flow from financing activities:
Issuance of common stock pursuant to stock option plans	933	415
Issuance of common stock pursuant to Employee Stock Purchase Plan	190	209
Proceeds from issuance of common stock, net	23,229	12,174
Taxes paid related to restricted stock issuance	(59)	(225)
Principal payments of capital lease obligations		(4,638)
Repayment of debt financing	(7,363)	775
Repayment on line of credit		(2,000)
Proceeds from notes payable		6,957
Debt issuance costs		22
Net cash provided by financing activities	16,930	13,689
Increase in cash and equivalents	8,619	7,320
Cash and cash equivalents, beginning of period	27,186	15,313
Cash and cash equivalents, end of period	35,805	22,633
Supplemental disclosure of cash flow information:
Interest paid	$ 92	127
Taxes paid		34
Issuance of common stock upon conversion of debentures		21,164
Right-of-use assets obtained in exchange for new operating lease liabilities		$ 69

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2019	$ 5,071	$ 196	$ 230,615	$ (224,325)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2019		19,546,151
Issuance of common stock relative to vesting of restricted stock	(225)		(225)
Issuance of common stock relative to vesting of restricted stock, shares		97,830
Issuance of common stock, net	12,174	$ 16	12,158
Issuance of common stock, net, shares		1,562,500
Issuance of common stock pursuant to stock option plans	417	$ 1	416
Issuance of common stock pursuant to stock option plans, shares		94,678
Issuance of common stock pursuant Employee Stock Purchase Plan	209		209
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		34,857
Issuance of stock upon conversion of Debentures	21,164	$ 18	21,146
Issuance of stock upon conversion of Debentures, shares		1,819,466
Stock-based compensation	2,542		2,542
Net loss	(16,007)			(16,007)
Ending Balance at Sep. 30, 2020	25,345	$ 231	266,861	(240,332)	(1,415)
Ending Balance, shares at Sep. 30, 2020		23,155,482
Beginning Balance at Jun. 30, 2020	26,492	$ 231	266,211	(238,535)	(1,415)
Beginning Balance, shares at Jun. 30, 2020		23,060,272
Issuance of common stock relative to vesting of restricted stock	(94)		(94)
Issuance of common stock relative to vesting of restricted stock, shares		29,106
Issuance of common stock pursuant to stock option plans	185		185
Issuance of common stock pursuant to stock option plans, shares		49,712
Issuance of common stock pursuant Employee Stock Purchase Plan	94		94
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		16,392
Stock-based compensation	465		465
Net loss	(1,797)			(1,797)
Ending Balance at Sep. 30, 2020	25,345	$ 231	266,861	(240,332)	(1,415)
Ending Balance, shares at Sep. 30, 2020		23,155,482
Beginning Balance at Dec. 31, 2020	30,525	$ 236	273,639	(241,935)	(1,415)
Beginning Balance, shares at Dec. 31, 2020		23,694,406
Issuance of common stock relative to vesting of restricted stock	(59)	$ 1	(60)
Issuance of common stock relative to vesting of restricted stock, shares		43,831
Issuance of common stock, net	23,229	$ 14	23,215
Issuance of common stock, net, shares		1,393,738
Issuance of common stock pursuant to stock option plans	933	$ 2	931
Issuance of common stock pursuant to stock option plans, shares		138,450
Issuance of common stock pursuant Employee Stock Purchase Plan	190		190
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		17,412
Stock-based compensation	2,102		2,102
Net loss	(7,099)			(7,099)
Ending Balance at Sep. 30, 2021	49,821	$ 253	300,017	(249,034)	(1,415)
Ending Balance, shares at Sep. 30, 2021		25,287,837
Beginning Balance at Jun. 30, 2021	51,027	$ 251	299,049	(246,858)	(1,415)
Beginning Balance, shares at Jun. 30, 2021		25,213,302
Issuance of common stock relative to vesting of restricted stock	(59)	$ 1	(60)
Issuance of common stock relative to vesting of restricted stock, shares		14,665
Issuance of common stock, net	297	$ 1	296
Issuance of common stock, net, shares		54,702
Issuance of common stock pursuant Employee Stock Purchase Plan	76		76
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		5,168
Stock-based compensation	656		656
Net loss	(2,176)			(2,176)
Ending Balance at Sep. 30, 2021	$ 49,821	$ 253	$ 300,017	$ (249,034)	$ (1,415)
Ending Balance, shares at Sep. 30, 2021		25,287,837

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2021, the results of operations of the Company for the three and nine-months ended September 30, 2021 and 2020, cash flows of the Company for the nine-months ended September 30, 2021 and 2020, and stockholders’ equity for the Company for the three and nine-months ended September 30, 2021 and 2020. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Segments The Company Risk and Uncertainty On March COVID-19 COVID-19 COVID-19. stay-at-home COVID-19 It is currently not possible to predict the duration of the pandemic or the time needed for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19 The Company’s results for the quarter ending September 30, 2021 reflect a negative impact from the COVID-19 COVID-19 t COVID-19 Although the Company did not experience any material impact to trade accounts receivable losses in the quarter ended September 30, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Recently Adopted Accounting Pronouncements There are no significant recently adopted accounting pronouncements. For a full list of the Company’s response to all relevant recent accounting pronouncements, please refer to Note 13 below. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the by Three months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,454 $ 2,358 $ 6,812 Service contracts 1,554 398 1,952 Supply and source usage agreements — 562 562 Professional services — 35 35 Other — — — $ 6,008 $ 3,353 $ 9,361 Timing of Revenue Recognition Goods transferred at a point in time $ 4,454 $ 2,393 $ 6,847 Services transferred over time 1,554 960 2,514 $ 6,008 $ 3,353 $ 9,361 Sales Channels Direct sales force $ 3,629 $ 1,403 $ 5,032 OEM partners 2,379 — 2,379 Channel partners — 1,950 1,950 $ 6,008 $ 3,353 $ 9,361 Nine months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 11,778 $ 6,580 $ 18,358 Service contracts 4,737 1,109 5,846 Supply and source usage agreements — 1,572 1,572 Professional services — 54 54 Other — — — $ 16,515 $ 9,315 $ 25,830 Timing of Revenue Recognition Goods transferred at a point in time $ 11,778 $ 6,633 $ 18,411 Services transferred over time 4,737 $ 2,682 7,419 $ 16,515 $ 9,315 $ 25,830 Sales Channels Direct sales force $ 10,691 $ 3,632 $ 14,323 OEM partners 5,824 — 5,824 Channel partners — 5,683 5,683 $ 16,515 $ 9,315 $ 25,830 Three months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,889 $ 1,038 $ 4,927 Service contracts 1,400 347 1,747 Supply and source usage agreements — 444 444 Professional services — 9 9 Other 2 — 2 $ 5,291 $ 1,838 $ 7,129 Timing of Revenue Recognition Goods transferred at a point in time $ 3,889 $ 1,051 $ 4,940 Services transferred over time 1,402 787 2,189 $ 5,291 $ 1,838 $ 7,129 Sales Channels Direct sales force $ 2,904 $ 857 $ 3,761 OEM partners 2,387 — 2,387 Channel partners — 981 981 $ 5,291 $ 1,838 $ 7,129 Nine months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 9,690 $ 2,959 $ 12,649 Service contracts 4,151 1,079 5,230 Supply and source usage agreements — 1,305 1,305 Professional services — 20 20 Other 43 — 43 $ 13,884 $ 5,363 $ 19,247 Timing of Revenue Recognition Goods transferred at a point in time $ 9,731 $ 3,039 $ 12,770 Services transferred over time 4,153 2,324 6,477 $ 13,884 $ 5,363 $ 19,247 Sales Channels Direct sales force $ 7,785 $ 3,131 $ 10,916 OEM partners 6,099 — 6,099 Channel partners — 2,232 2,232 $ 13,884 $ 5,363 $ 19,247 Products. Service Contracts. non-lease Supply and Source Usage Agreements. These agreements represent a separate performance obligation of the Company. The Company allocates revenue to each performance obligation based on the SSP. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current contract assets are a component of other assets. non-current Contract balances Contract balances Balance at Balance at September 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts $ 11,792 $ 10,027 Current 658 481 Non-current 1,602 1,434 Contract liabilities, which are included in “Deferred 6,450 6,384 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally invoiced in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn ed Contract liabilities September 30, 2021 December 31, 2020 Short term $ 5,930 $ 6,117 Long term 520 267 Total $ 6,450 $ 6,384 Changes in deferred revenue from contracts with customers were as follows (in thousands): Nine Months Ended Balance at beginning of period $ 6,384 Deferral of revenue 9,761 Recognition of deferred revenue (9,695 ) Balance at end of period $ 6,450 The Company are the million in 2023, $1.1 million in 2024, $1.1 million in 2025 and $0.2 million in 2026.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 2 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Net loss $ (2,176 ) $ (1,797 ) $ (7,099 ) $ (16,007 ) Shares used in the calculation of basic and diluted net loss per share 25,053 23,173 24,662 21,827 Diluted shares used in the calculation of net loss per share 25,053 23,173 24,662 21,827 Net loss per share—basic and diluted $ (0.09 ) $ (0.08 ) $ (0.29 ) $ (0.73 ) The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the As of 2021 2020 Stock options 2,509,511 1,971,704 Restricted stock 1,750 29,166 Total 2,511,261 2,000,870

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Note 3 – Inventory Inventory is valued at the lower of cost or net realizable value, with cost determined by the first-in, first-out and September 30, 2021 December 31, 2020 Raw materials $ 1,845 $ 1,538 Work in process 104 76 Finished Goods 1,567 1,774 Inventory Gross 3,516 3,388 Inventory Reserve (225 ) (244 ) Inventory Net $ 3,290 $ 3,144

Financing Arrangements

Financing Arrangements	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Financing Arrangements	Note 4 – Financing Arrangements (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. I the In connection with the Loan Agreement, the Company incurred approximately $141,000 of closing costs. The closing costs have been deduced from the carrying value of the debt and will be amortized through March 30, 2022, the maturity date of the Term Loan. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $122,500 final payment, a termination fee of $50,000 and other closing costs totaling approximately $15,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. The Company recorded a loss on extinguishment of approximately $386,000 related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized and other closing costs from origination of the loan. (b) Loan and Security Agreement – Silicon Valley Bank On August 7, 2017, the Company entered into a Loan and Security Agreement, which was subsequently modified several times through November 1, 2019 (as amended, the “SVB Loan Agreement”), with Silicon Valley Bank that provided an initial term loan facility of $6.0 million and a $4.0 million revolving line of credit. On March 30, 2020, the Company elected to repay all outstanding obligations (including accrued interest) and retire the SVB Loan Agreement. The Company accounted for this repayment and retirement as an extinguishment of the SVB Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $510,000 final payment, a termination fee of $114,000 and other costs totaling $10,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. In March 2020 the Company recorded a loss on extinguishment of approximately $341,000 related to the repayment and retirement of the SVB Loan Agreement. The loss on extinguishment was composed of approximately $185,000 for the unaccrued final payment, $114,000 termination fee, and $42,000 of unamortized and other closing costs. (c) Convertible Debentures On December 20, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited investors (the “Investors”), including, but not limited to, all directors and executive officers of the Company at the time, pursuant to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”) with an aggregate principal amount of approximately $7.0 million in a private placement. On February 21, 2020 (the “Conversion Date”), the conditions permitting a forced conversion were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures. As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make-whole provisions in the Convertible Debentures, the Company also issued an additional 76,966 shares of its common stock. The make-whole amount represented the total interest which would have accrued through the maturity date of the Convertible Debentures, less the amounts previously paid, totaling $697,000. The conversion prices related to the make-whole amount were dependent on whether the Investors were related parties or unrelated third parties. Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures The Company had previously elected to make a one-time, irrevocable As of the December 31, 2019 valuation and the prior measurement dates, the Company utilized a Monte Carlo simulation model to estimate the fair value of the Convertible Debentures. The simulation model was designed to capture the potential settlement features of the Convertible Debentures, in conjunction with simulated changes in the Company’s stock price and the probability of certain events occurring. The simulation utilized 100,000 trials or simulations to determine the estimated fair value. The simulation utilized the assumptions that if the Company was able to exercise its forced conversion right (if the requirements to do so were met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios. If neither event occurred during a simulated trial, the simulation assumed that the Investor would hold the Convertible Debentures until the maturity date. The value of the cash flows associated with each potential settlement were discounted to present value in each trial based on either the risk-free rate (for an equity settlement) or the effective discount rate (for a redemption or cash settlement). The Company also recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% of scenarios when the requirements were met, the final valuation was based on the actual results of the forced conversion. As such, the Company based the final fair value adjustment to the Convertible Debentures just prior to conversion on the number of shares of common stock that were issued to the Investors upon conversion and the fair value of the Company’s common stock as of the Conversion Date. The key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A Probability of default event 1 0.45 % N/A Utilization of Forced Conversion (if available) 1 100.00 % 100.00 % Exercise of Default Redemption (if available) 1 100.00 % N/A Effective discount rate 1 18.52 % N/A 1 Represents a Level 3 unobservable input, as defined in Note 8—Fair Value Measurements, below. The Company’s stock price was based on the closing stock price on the valuation date. The conversion price was based on the contractual conversion price included in the SPA. The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures, or remaining term under the expectation of the Company’s election of its forced conversion right. The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of public companies. The risk-free rate was determined based on U.S. Treasury securities with similar terms. The probability of the occurrence of a default event was based on Bloomberg’s 1-year The utilization of the forced conversion right and the default redemption right was based on management’s best estimate of both features being exercised upon the occurrence of the related contingent events. The effective discount rate utilized at the December 31, 2019 valuation date was based on yields on CCC-rated The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970 In February 2020 the Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for period through the Conversion Date which is described in the additional fair value disclosures related to the Convertible Debentures in Note 8. Upon the consummation of the forced conversion, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million, which was reclassified to stockholders’ equity. (d) Principal and Interest Payments Related to Financing Arrangements The Company no longer has any financing agreements as of September 30, 2021. The following amounts are included in interest expense in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cash interest expense $ — $ 94 $ 141 $ 232 Interest on convertible debentures — — — 49 Accrual of notes payable final payment — 8 — 47 Amortization of debt costs — 13 — 32 Total interest expense $ — $ 115 $ 141 $ 360

Leases Commitments

Leases Commitments	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 5 – Lease Commitments Under ASC 842, “Leases” (“ASC 842”), the Company determines if an arrangement contains a lease at inception. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (i.e., an identified asset) for a period of time in exchange for consideration. Leases are classified as either operating leases or financing leases. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. The Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company determines the incremental borrowing rates for its leases by applying its applicable, fully collateralized borrowing rate, with adjustment as appropriate for the lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement re-measurement right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Components of Leases: The Company has leases for office space and office equipment. The leases have remaining lease terms ranging from less than one year to four years and six months as of September 30, 2021. The components of lease expense for the three and nine months ended September 30, 2021 are as follows (in thousands): Lease Cost Classification Three Months Ended Nine Months Ended Operating lease cost—Right of Use Asset Operating expenses $ 214 $ 649 Operating lease cost—Variable Operating expenses 63 $ 127 Total $ 277 $ 776 Other information related to leases was as follows (in thousands): Three Months Ended Nine Months Ended Cash paid from operating cash flows for operating leases $ 230 $ 581 As of September 30, Weighted-average remaining lease term of operating leases (in years) 1.47 Weighted-average discount rate for operating leases 5.5 % Maturity of the Company’s lease liabilities as of September 30, 2021 was as follows (in thousands): As of September 30, 2021: Operating 2021 229 2022 899 2023 211 2024 5 Total lease payments 1,344 Less: imputed interest (57 ) Total lease liabilities 1,287 Less: current portion of lease liabilities (856 ) Long-term lease liabilities $ 431

Stockholders Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2021
Federal Home Loan Banks [Abstract]
Stockholders Equity	Note 6 – Stockholders Equity (a) Financing Activity On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company. (b) Stock-Based Compensation The Company nded Three Months Ended Nine Months Ended 2021 2020 2021 2020 Average risk-free interest rate 0.41 % 0.15 % 0.28 % 0.79 % Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 65.57% to 67.42 % 66.0% to 66.0 % 65.57% to 67.42 % 50.2 to 65.7 % Weighted average exercise price $15.04 $8.84 $16.61 $10.08 Weighted average fair value $6.18 $4.11 $7.34 $4.34 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenue $ 3 $ 3 $ 20 $ 28 Engineering and product development 73 64 281 406 Marketing and sales 149 61 629 608 General and administrative 431 337 1,172 1,500 $ 656 $ 465 $ 2,102 $ 2,542 As of September 30, 2021, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 4,972 Weighted average term 1.3 The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date. The Company The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of September 30, Aggregate intrinsic value 2021 2020 Stock options $ 8,765 $ 6,679 Restricted stock 19 257 The Company million and million Employee Stock Purchase Plan In December 2019, the 2019 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors (the “Board”) and approved by stockholders, effective January 1, 2020. The ESPP Substantially Any eligible employee can enroll in the ESPP as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $ 25,000 The Company issued 5,168 and 17,412 shares under the ESPP in the three and nine-months ended September 30, 2021 respectively. The Company recorded approximately $23,000 and $76,000 of stock-based compensation expense pursuant to ESPP for the three and nine-months ended September 30, 2021 respectively. The

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $4.3 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations. Litigation In December 2016, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Invivo Corporation (“Invivo”). In accordance with the Asset Purchase Agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 (the “Escrowed Amount”) for net proceeds of approximately $2.9 million. On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (the “Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No. 1:18-cv-08083-GBD, one-time non-conditional The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. The Company may be a party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable and convertible debentures. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments (except the Convertible Debentures, which were measured at fair value in accordance with the fair value option election) approximated fair value as of February 21, 2020 and December 31, 2019. The Company’s assets and liabilities that are measured at fair value on a recurring basis include the Company’s money market accounts and Convertible Debentures. The money market accounts are included in cash and cash equivalents in the accompanying consolidated balance sheet and are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The Convertible Debentures were recorded as a separate component of the Company’s consolidated balance sheet and are considered a Level 3 measurement due to the utilization of significant unobservable inputs in their valuation. See Note 4(b) for a discussion of these fair value measurements. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 27,186 — — $ 27,186 Total Assets $ 27,186 — — $ 27,186 Fair Value Measurements (in thousands) as of September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 35,805 — — $ 35,805 Total Assets $ 35,805 — — $ 35,805

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 – Income Taxes The Coronavirus Aid, Relief, and Economic Security Act was enacted on March 27, 2020 and did not have a material impact on the Company’s provision for income taxes for the three and nine months ended September 30, 2021. The Company recorded an income tax provision of $0 for the three and nine months ended September 30, 2021, and $3,000 and $34,000 for the three and nine months ended September 30, 2020. The Company adopted ASU 2019-12 non-income non-income 2019-12. The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $4,000 related to tax amortizable goodwill. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2021. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 10 – Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value. The Company has two operating segments, Detection and Therapy, as further discussed in Note 12 below. A rollforward of goodwill activity by reportable segment is as follows (in thousands) : Consolidated Detection Therapy Total Accumulated Goodwill $ 47,937 $ — $ — $ 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Balance at December 31, 2020 and September 30, 2021 — 8,362 — 8,362 There were no impairment indicators present as of September 30, 2021.

Long-lived assets

Long-lived assets	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 11 – Long-lived assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value. There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.” The Company determined there were no such triggering events in the quarter ended September 30, 2021.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Reporting	Note 12 – Segment Reporting Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM is the Chief Executive Officer. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, “Axxent,” and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track assets by operating segment and the Company’s CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Segment revenues: Detection $ 6,008 $ 5,291 $ 16,515 $ 13,885 Therapy 3,353 1,838 9,315 5,362 Total Revenue $ 9,361 $ 7,129 $ 25,830 $ 19,247 Segment gross profit: Detection $ 5,058 $ 4,227 $ 13,788 $ 11,227 Therapy 1,654 798 4,751 2,665 Segment gross profit $ 6,712 $ 5,025 $ 18,539 $ 13,892 Segment operating income (loss): Detection $ 671 $ 866 $ 1,664 $ 721 Therapy (173 ) (711 ) (735 ) (2,149 ) Segment operating income (loss) $ 498 $ 155 $ 929 $ (1,428 ) General, administrative, depreciation and amortization expense $ (2,679 ) $ (1,844 ) $ (7,513 ) $ (6,465 ) Interest expense — (115 ) (141 ) (360 ) Other income 5 10 12 85 Loss on extinguishment of debt — — (386 ) (341 ) Fair value of convertible debentures — — — (7,464 ) Loss before income tax $ (2,176 ) $ (1,794 ) $ (7,099 ) $ (15,973 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Text Block [Abstract]
Recent Accounting Pronouncements	Note 13 – Recent Accounting Pronouncements Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standard Board (the “FASB”) issued ASU 2019-12, 2019-12”). 2019-12 2019-12 2019-12 non-income Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, “Financial (“ASU 2016-13”), ASU 2016-13 2016-13 2016-13 2016-13 In March 2020, the FASB issued ASU 2020-04, 2020-04”). ASU 2020-04 2020-04 2020-04 In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40): 2020-06”). 2020-06 2020-06 2020-06 2020-06 2020-06

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events None.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2021, the results of operations of the Company for the three and nine-months ended September 30, 2021 and 2020, cash flows of the Company for the nine-months ended September 30, 2021 and 2020, and stockholders’ equity for the Company for the three and nine-months ended September 30, 2021 and 2020. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K
Segments	Segments The Company
Risk and Uncertainty	Risk and Uncertainty On March COVID-19 COVID-19 COVID-19. stay-at-home COVID-19 It is currently not possible to predict the duration of the pandemic or the time needed for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19 The Company’s results for the quarter ending September 30, 2021 reflect a negative impact from the COVID-19 COVID-19 t COVID-19 Although the Company did not experience any material impact to trade accounts receivable losses in the quarter ended September 30, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements There are no significant recently adopted accounting pronouncements. For a full list of the Company’s response to all relevant recent accounting pronouncements, please refer to Note 13 below.
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the by Three months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,454 $ 2,358 $ 6,812 Service contracts 1,554 398 1,952 Supply and source usage agreements — 562 562 Professional services — 35 35 Other — — — $ 6,008 $ 3,353 $ 9,361 Timing of Revenue Recognition Goods transferred at a point in time $ 4,454 $ 2,393 $ 6,847 Services transferred over time 1,554 960 2,514 $ 6,008 $ 3,353 $ 9,361 Sales Channels Direct sales force $ 3,629 $ 1,403 $ 5,032 OEM partners 2,379 — 2,379 Channel partners — 1,950 1,950 $ 6,008 $ 3,353 $ 9,361 Nine months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 11,778 $ 6,580 $ 18,358 Service contracts 4,737 1,109 5,846 Supply and source usage agreements — 1,572 1,572 Professional services — 54 54 Other — — — $ 16,515 $ 9,315 $ 25,830 Timing of Revenue Recognition Goods transferred at a point in time $ 11,778 $ 6,633 $ 18,411 Services transferred over time 4,737 $ 2,682 7,419 $ 16,515 $ 9,315 $ 25,830 Sales Channels Direct sales force $ 10,691 $ 3,632 $ 14,323 OEM partners 5,824 — 5,824 Channel partners — 5,683 5,683 $ 16,515 $ 9,315 $ 25,830 Three months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,889 $ 1,038 $ 4,927 Service contracts 1,400 347 1,747 Supply and source usage agreements — 444 444 Professional services — 9 9 Other 2 — 2 $ 5,291 $ 1,838 $ 7,129 Timing of Revenue Recognition Goods transferred at a point in time $ 3,889 $ 1,051 $ 4,940 Services transferred over time 1,402 787 2,189 $ 5,291 $ 1,838 $ 7,129 Sales Channels Direct sales force $ 2,904 $ 857 $ 3,761 OEM partners 2,387 — 2,387 Channel partners — 981 981 $ 5,291 $ 1,838 $ 7,129 Nine months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 9,690 $ 2,959 $ 12,649 Service contracts 4,151 1,079 5,230 Supply and source usage agreements — 1,305 1,305 Professional services — 20 20 Other 43 — 43 $ 13,884 $ 5,363 $ 19,247 Timing of Revenue Recognition Goods transferred at a point in time $ 9,731 $ 3,039 $ 12,770 Services transferred over time 4,153 2,324 6,477 $ 13,884 $ 5,363 $ 19,247 Sales Channels Direct sales force $ 7,785 $ 3,131 $ 10,916 OEM partners 6,099 — 6,099 Channel partners — 2,232 2,232 $ 13,884 $ 5,363 $ 19,247 Products. Service Contracts. non-lease Supply and Source Usage Agreements. These agreements represent a separate performance obligation of the Company. The Company allocates revenue to each performance obligation based on the SSP. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current contract assets are a component of other assets. non-current Contract balances Contract balances Balance at Balance at September 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts $ 11,792 $ 10,027 Current 658 481 Non-current 1,602 1,434 Contract liabilities, which are included in “Deferred 6,450 6,384 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally invoiced in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn ed Contract liabilities September 30, 2021 December 31, 2020 Short term $ 5,930 $ 6,117 Long term 520 267 Total $ 6,450 $ 6,384 Changes in deferred revenue from contracts with customers were as follows (in thousands): Nine Months Ended Balance at beginning of period $ 6,384 Deferral of revenue 9,761 Recognition of deferred revenue (9,695 ) Balance at end of period $ 6,450 The Company are the million in 2023, $1.1 million in 2024, $1.1 million in 2025 and $0.2 million in 2026.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents the by Three months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,454 $ 2,358 $ 6,812 Service contracts 1,554 398 1,952 Supply and source usage agreements — 562 562 Professional services — 35 35 Other — — — $ 6,008 $ 3,353 $ 9,361 Timing of Revenue Recognition Goods transferred at a point in time $ 4,454 $ 2,393 $ 6,847 Services transferred over time 1,554 960 2,514 $ 6,008 $ 3,353 $ 9,361 Sales Channels Direct sales force $ 3,629 $ 1,403 $ 5,032 OEM partners 2,379 — 2,379 Channel partners — 1,950 1,950 $ 6,008 $ 3,353 $ 9,361 Nine months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 11,778 $ 6,580 $ 18,358 Service contracts 4,737 1,109 5,846 Supply and source usage agreements — 1,572 1,572 Professional services — 54 54 Other — — — $ 16,515 $ 9,315 $ 25,830 Timing of Revenue Recognition Goods transferred at a point in time $ 11,778 $ 6,633 $ 18,411 Services transferred over time 4,737 $ 2,682 7,419 $ 16,515 $ 9,315 $ 25,830 Sales Channels Direct sales force $ 10,691 $ 3,632 $ 14,323 OEM partners 5,824 — 5,824 Channel partners — 5,683 5,683 $ 16,515 $ 9,315 $ 25,830 Three months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,889 $ 1,038 $ 4,927 Service contracts 1,400 347 1,747 Supply and source usage agreements — 444 444 Professional services — 9 9 Other 2 — 2 $ 5,291 $ 1,838 $ 7,129 Timing of Revenue Recognition Goods transferred at a point in time $ 3,889 $ 1,051 $ 4,940 Services transferred over time 1,402 787 2,189 $ 5,291 $ 1,838 $ 7,129 Sales Channels Direct sales force $ 2,904 $ 857 $ 3,761 OEM partners 2,387 — 2,387 Channel partners — 981 981 $ 5,291 $ 1,838 $ 7,129 Nine months ended September 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 9,690 $ 2,959 $ 12,649 Service contracts 4,151 1,079 5,230 Supply and source usage agreements — 1,305 1,305 Professional services — 20 20 Other 43 — 43 $ 13,884 $ 5,363 $ 19,247 Timing of Revenue Recognition Goods transferred at a point in time $ 9,731 $ 3,039 $ 12,770 Services transferred over time 4,153 2,324 6,477 $ 13,884 $ 5,363 $ 19,247 Sales Channels Direct sales force $ 7,785 $ 3,131 $ 10,916 OEM partners 6,099 — 6,099 Channel partners — 2,232 2,232 $ 13,884 $ 5,363 $ 19,247
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, current and non-current Contract balances Balance at Balance at September 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts $ 11,792 $ 10,027 Current 658 481 Non-current 1,602 1,434 Contract liabilities, which are included in “Deferred 6,450 6,384
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows (in thousands): Nine Months Ended Balance at beginning of period $ 6,384 Deferral of revenue 9,761 Recognition of deferred revenue (9,695 ) Balance at end of period $ 6,450
Accounting Standards Update 2016-02 [Member]
Summary of Changes in Deferred Revenue	Contract liabilities September 30, 2021 December 31, 2020 Short term $ 5,930 $ 6,117 Long term 520 267 Total $ 6,450 $ 6,384

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Net loss $ (2,176 ) $ (1,797 ) $ (7,099 ) $ (16,007 ) Shares used in the calculation of basic and diluted net loss per share 25,053 23,173 24,662 21,827 Diluted shares used in the calculation of net loss per share 25,053 23,173 24,662 21,827 Net loss per share—basic and diluted $ (0.09 ) $ (0.08 ) $ (0.29 ) $ (0.73 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the As of 2021 2020 Stock options 2,509,511 1,971,704 Restricted stock 1,750 29,166 Total 2,511,261 2,000,870

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Current Inventory	September 30, 2021 December 31, 2020 Raw materials $ 1,845 $ 1,538 Work in process 104 76 Finished Goods 1,567 1,774 Inventory Gross 3,516 3,388 Inventory Reserve (225 ) (244 ) Inventory Net $ 3,290 $ 3,144

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures	The key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A Probability of default event 1 0.45 % N/A Utilization of Forced Conversion (if available) 1 100.00 % 100.00 % Exercise of Default Redemption (if available) 1 100.00 % N/A Effective discount rate 1 18.52 % N/A
Schedule of Fair Value and Principal Value of Convertible Debentures	The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970
Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cash interest expense $ — $ 94 $ 141 $ 232 Interest on convertible debentures — — — 49 Accrual of notes payable final payment — 8 — 47 Amortization of debt costs — 13 — 32 Total interest expense $ — $ 115 $ 141 $ 360

Leases Commitments (Tables)

Leases Commitments (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The components of lease expense for the three and nine months ended September 30, 2021 are as follows (in thousands): Lease Cost Classification Three Months Ended Nine Months Ended Operating lease cost—Right of Use Asset Operating expenses $ 214 $ 649 Operating lease cost—Variable Operating expenses 63 $ 127 Total $ 277 $ 776 Other information related to leases was as follows (in thousands): Three Months Ended Nine Months Ended Cash paid from operating cash flows for operating leases $ 230 $ 581 As of September 30, Weighted-average remaining lease term of operating leases (in years) 1.47 Weighted-average discount rate for operating leases 5.5 %
Summary of Detained Information of Lease Liabilities	Maturity of the Company’s lease liabilities as of September 30, 2021 was as follows (in thousands): As of September 30, 2021: Operating 2021 229 2022 899 2023 211 2024 5 Total lease payments 1,344 Less: imputed interest (57 ) Total lease liabilities 1,287 Less: current portion of lease liabilities (856 ) Long-term lease liabilities $ 431

Stockholders Equity (Tables)

Stockholders Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Three Months Ended Nine Months Ended 2021 2020 2021 2020 Average risk-free interest rate 0.41 % 0.15 % 0.28 % 0.79 % Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 65.57% to 67.42 % 66.0% to 66.0 % 65.57% to 67.42 % 50.2 to 65.7 % Weighted average exercise price $15.04 $8.84 $16.61 $10.08 Weighted average fair value $6.18 $4.11 $7.34 $4.34
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenue $ 3 $ 3 $ 20 $ 28 Engineering and product development 73 64 281 406 Marketing and sales 149 61 629 608 General and administrative 431 337 1,172 1,500 $ 656 $ 465 $ 2,102 $ 2,542
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period	As of September 30, 2021, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 4,972 Weighted average term 1.3
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of September 30, Aggregate intrinsic value 2021 2020 Stock options $ 8,765 $ 6,679 Restricted stock 19 257

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 27,186 — — $ 27,186 Total Assets $ 27,186 — — $ 27,186 Fair Value Measurements (in thousands) as of September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 35,805 — — $ 35,805 Total Assets $ 35,805 — — $ 35,805

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Roll Forward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows (in thousands) : Consolidated Detection Therapy Total Accumulated Goodwill $ 47,937 $ — $ — $ 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Balance at December 31, 2020 and September 30, 2021 — 8,362 — 8,362

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Segment revenues: Detection $ 6,008 $ 5,291 $ 16,515 $ 13,885 Therapy 3,353 1,838 9,315 5,362 Total Revenue $ 9,361 $ 7,129 $ 25,830 $ 19,247 Segment gross profit: Detection $ 5,058 $ 4,227 $ 13,788 $ 11,227 Therapy 1,654 798 4,751 2,665 Segment gross profit $ 6,712 $ 5,025 $ 18,539 $ 13,892 Segment operating income (loss): Detection $ 671 $ 866 $ 1,664 $ 721 Therapy (173 ) (711 ) (735 ) (2,149 ) Segment operating income (loss) $ 498 $ 155 $ 929 $ (1,428 ) General, administrative, depreciation and amortization expense $ (2,679 ) $ (1,844 ) $ (7,513 ) $ (6,465 ) Interest expense — (115 ) (141 ) (360 ) Other income 5 10 12 85 Loss on extinguishment of debt — — (386 ) (341 ) Fair value of convertible debentures — — — (7,464 ) Loss before income tax $ (2,176 ) $ (1,794 ) $ (7,099 ) $ (15,973 )

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)Segment
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment | Segment	2
2021 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	$ 2.3
2022 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	4.3
2023 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.7
2024 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.1
2025 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.1
2026 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	$ 0.2

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 9,361	$ 7,129	$ 25,830	$ 19,247
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	6,812	4,927	18,358	12,649
Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,952	1,747	5,846	5,230
Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	562	444	1,572	1,305
Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	35	9	54	20
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		2		43
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	6,847	4,940	18,411	12,770
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,514	2,189	7,419	6,477
Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	5,032	3,761	14,323	10,916
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,379	2,387	5,824	6,099
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,950	981	5,683	2,232
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	6,008	5,291	16,515	13,884
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,454	3,889	11,778	9,690
Detection [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,554	1,400	4,737	4,151
Detection [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		2		43
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,454	3,889	11,778	9,731
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,554	1,402	4,737	4,153
Detection [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,629	2,904	10,691	7,785
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,379	2,387	5,824	6,099
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,353	1,838	9,315	5,363
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,358	1,038	6,580	2,959
Therapy [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	398	347	1,109	1,079
Therapy [Member] | Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	562	444	1,572	1,305
Therapy [Member] | Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	35	9	54	20
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,393	1,051	6,633	3,039
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	960	787	2,682	2,324
Therapy [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,403	857	3,632	3,131
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 1,950	$ 981	$ 5,683	$ 2,232

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in ‘Trade accounts receivable'	$ 11,792	$ 10,027
Current contract assets, which are included in "Prepaid and other assets"	658	481
Non-current contract assets, which are included in "other assets"	1,602	1,434
Contract liabilities, which are included in "Deferred revenue"	$ 6,450	$ 6,384

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 6,450	$ 6,384
Short-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	5,930	6,117
Long-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 520	$ 267

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 6,384
Deferral of revenue	9,761
Recognition of deferred revenue	(9,695)
Balance at end of period	$ 6,450

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (2,176)	$ (1,797)	$ (7,099)	$ (16,007)
Shares used in the calculation of basic and diluted net loss per share	25,053	23,173	24,662	21,827
Effect of dilutive securities:
Diluted shares used in the calculation of net loss per share	25,053	23,173	24,662	21,827
Net loss per share - basic and diluted	$ (0.09)	$ (0.08)	$ (0.29)	$ (0.73)

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,511,261	2,000,870
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,509,511	1,971,704
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,750	29,166

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory reserve	$ 225	$ 244

Inventory - Schedule of Current

Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,845	$ 1,538
Work in process	104	76
Finished Goods	1,567	1,774
Inventory Gross	3,516	3,388
Inventory Reserve	(225)	(244)
Inventory Net	$ 3,290	$ 3,144

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail)	Apr. 27, 2021USD ($)	Mar. 30, 2020USD ($)	Feb. 29, 2020USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2021USD ($)customerTrial$ / sharesshares	Sep. 30, 2020USD ($)	Feb. 21, 2021USD ($)	Feb. 21, 2020USD ($)	Dec. 31, 2019USD ($)	Aug. 07, 2017USD ($)
Debt Instrument [Line Items]
Line of credit, closing costs				$ 141,000	$ 141,000
Debt insrument redemption description					The simulation utilized the assumptions that if the Company was able to exercise its forced conversion right (if the requirements to do so were met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios.
Loss from fair value of the convertible debentures			$ 7,500,000
Final payment of loan		$ 510,000
Gain (Loss) on Extinguishment of Debt				0	$ (386,000)	$ (341,000)
Reclassified the fair value of convertible debentures							$ 21,200,000	$ 21,164,000	$ 13,642,000
Obligations repaid	$ 7,354,283,000					$ 2,000,000
ICAD Western Alliance Bank [Member]
Debt Instrument [Line Items]
Final payment of loan					122,500,000
Termination Loans				50,000,000	50,000,000
Other Costs					15,000,000
Gain (Loss) on Extinguishment of Debt					386,000,000
ICAD Western Alliance Bank [Member] | Debt Prepayment Cost [Member]
Debt Instrument [Line Items]
Debt prepayment cost					140,000,000
ICAD Western Alliance Bank [Member] | Final Payment Of Loan [Member]
Debt Instrument [Line Items]
Final payment of loan					122,000,000
ICAD Western Alliance Bank [Member] | Termination Loans [Member]
Debt Instrument [Line Items]
Termination Loans				65,000,000	65,000,000
ICAD Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member]
Debt Instrument [Line Items]
Unamortized closing costs				58,000,000	58,000,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Termination Loans				$ 114,000	$ 114,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Final payment of loan		185,000
Termination Loans		114,000
Other Costs		10,000
Gain (Loss) on Extinguishment of Debt		341,000
Unamortized closing costs		$ 42,000
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Interest Rate During Period		3.25%
Interest Rate Description					6.0
Western Alliance Bank [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		4.25%
Western Alliance Bank [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		1.00%
Convertible Debt [Member]
Debt Instrument [Line Items]
Aggregate principal amount									$ 7,000,000
Debt conversion, conversion price per share | $ / shares				$ 4	$ 4
Convertible debenture Number of instrumnts converted | customer					1,742,500
Shares issued up on conversion | shares					1,816,466
Convertible Debt [Member] | Make Whole Provision [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 697,000	$ 697,000
Convertible debenture Number of instrumnts converted | customer					76,966
Convertible Debt [Member] | Monte Carlo Simulation [Member]
Debt Instrument [Line Items]
Number of trials to detremine fair value | Trial					100,000
Term Loan A [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		$ 7,000,000
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		$ 5,000,000								$ 4,000,000

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures (Detail) - Convertible Debt [Member]		Feb. 21, 2020yr	Dec. 31, 2019yr
Company's Stock Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		11.64	7.77
Conversion Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		4	4
Remaining Term (Years) [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		0	1.97
Equity Volatility [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			49
Risk Free Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			1.57
Probability of default event [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		0.45
Utilization of Forced Conversion [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	100	100
Exercise of Default Redemption [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		100
Effective discount rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		18.52
[1]	Represents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below.

Financing Arrangements - Sche_2

Financing Arrangements - Schedule of Fair Value and Principal Value of Convertible Debentures (Detail) - USD ($) $ in Thousands	Feb. 21, 2021	Feb. 21, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Fair value, in accordance with fair value option	$ 21,200	$ 21,164	$ 13,642
Principal value outstanding		$ 6,970	$ 6,970

Financing Arrangements - Intere

Financing Arrangements - Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Interest Expense [Line Items]
Cash interest expense	$ 0	$ 94	$ 141	$ 232
Interest on convertible debentures				49
Accrual of notes payable final payment		8		47
Amortization of debt costs		13		32
Total interest expense	$ 0	$ 115	$ 141	$ 360

Leases Commitments - Additional

Leases Commitments - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2021
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	4 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year

Leases Commitments - Schedule o

Leases Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost—Right of Use Asset	$ 214	$ 649
Operating lease cost—Variable	63	127
Finance lease costs
Total	277	776
Cash paid from operating cash flows for operating leases	$ 230	$ 581
Weighted-average remaining lease term of operating leases (in years)	1 year 5 months 19 days	1 year 5 months 19 days
Weighted-average discount rate for operating leases	5.50%	5.50%

Leases Commitments - Summary of

Leases Commitments - Summary of Detained Information of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021	$ 229
2022	899
2023	211
2024	5
Total	1,344
Less: imputed interest	(57)
Total lease liabilities	1,287
Less: current portion of lease liabilities	(856)
Total lease liabilities	$ 431

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Detail) - USD ($)	Mar. 02, 2021	Dec. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from Issue of common stock					$ 23,229,000	$ 12,174,000
Underwritten public offering shares	1,393,738
Offering price, per share	$ 18
Gross proceeds from sale of units	$ 25,100,000
Net proceeds from sale of units	$ 23,200,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	0	22,488	0
Number of shares vested			19,863		49,904
Intrinsic value of restricted shares that vested			$ 0		$ 500,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, Issued			54,702		138,450
Net proceeds from Issue of common stock			$ 300,000		$ 900,000
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of voting power		5.00%
Description of employee stock purchase plan					Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.
Number of shares issued, Employee Stock Purchase Plans		950,000	5,168		17,412
Stock-based compensation expense			$ 23,000		$ 76,000
Employee-related Liabilities, Current			$ 89,000		$ 89,000
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			403,000		831,938

Stockholders Equity - Options G

Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	0.41%	0.15%	0.28%	0.79%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 15.04	$ 8.84	$ 16.61	$ 10.08
Weighted average fair value	$ 6.18	$ 4.11	$ 7.34	$ 4.34
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	65.57%	66.00%	65.57%	50.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	67.42%	66.00%	67.42%	65.70%

Stockholders Equity - Stock-Bas

Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 656	$ 465	$ 2,102	$ 2,542
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	3	3	20	28
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	73	64	281	406
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	149	61	629	608
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 431	$ 337	$ 1,172	$ 1,500

Stockholders Equity - Unrecogni

Stockholders Equity - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]
Remaining expense	$ 4,972
Weighted average term	1 year 3 months 18 days

Stockholders Equity - Aggregate

Stockholders Equity - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option	$ 8,765	$ 6,679
Restricted stock	$ 19	$ 257

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 13, 2021	Jun. 30, 2021	Sep. 30, 2021	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables			$ 4,300
Minimum royalty obligations			$ 200
Cash paid on litigation	$ 85,000
Escrowed amount payable by other party		$ 50,000
Litigation Settlement, Expense		$ 93,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Schedule Of Leases [Line Items]
Sale and transfer of intangible assets					$ 3,200
Holdback reserve related to sale and transfer of intangible assets				$ 350,000
Proceeds from sale and transfer of intangible assets				$ 2,900

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Total Assets	$ 35,805	$ 27,186
Money Market Accounts [Member]
Assets
Total Assets	35,805	27,186
Level 1 [Member]
Assets
Total Assets	35,805	27,186
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 35,805	$ 27,186

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0		$ 0
Deferred Tax Liabilities, Goodwill	4,000		4,000
Income tax provision	$ 0	$ 3,000	$ 0	$ 34,000

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Impairment	$ 0

Goodwill - Roll Forward of Good

Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accumulated Goodwill	$ 47,937
Accumulated impairment	(26,828)
Acquisition measurement period adjustments	116
Sale of MRI assets	(394)
Impairment	(19,716)
Goodwill, Ending Balance	8,362	$ 8,362
DermEbx And Radion [Member]
Acquisition cost	6,154
VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Consolidated Reporting Unit [Member]
Accumulated Goodwill	47,937
Accumulated impairment	(26,828)
Fair value allocation	(21,109)
Detection [Member]
Fair value allocation	7,663
Sale of MRI assets	(394)
Goodwill, Ending Balance	8,362	$ 8,362
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Therapy [Member]
Fair value allocation	13,446
Acquisition measurement period adjustments	116
Impairment	(19,716)
Therapy [Member] | DermEbx And Radion [Member]
Acquisition cost	$ 6,154

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2021Segment
Schedule Of Geographical Information [Line Items]
Number of reporting segments	2

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment revenues:
Total Revenue	$ 9,361	$ 7,129	$ 25,830	$ 19,247
Segment gross profit:
Segment gross profit	6,712	5,025	18,539	13,892
Segment operating income (loss):
Segment operating income (loss)	498	155	929	(1,428)
General, administrative, depreciation and amortization expense	(2,679)	(1,844)	(7,513)	(6,465)
Interest expense	0	(115)	(141)	(360)
Other income	5	10	12	85
Loss on extinguishment of debt	0		(386)	(341)
Fair value of convertible debentures				(7,464)
Loss before income tax expense	(2,176)	(1,794)	(7,099)	(15,973)
Product [Member]
Segment revenues:
Total Revenue	6,320	4,538	16,429	11,220
Service [Member]
Segment revenues:
Total Revenue	3,041	2,591	9,401	8,027
Detection [Member]
Segment gross profit:
Segment gross profit	5,058	4,227	13,788	11,227
Segment operating income (loss):
Segment operating income (loss)	671	866	1,664	721
Detection [Member] | Product [Member]
Segment revenues:
Total Revenue	6,008	5,291	16,515	13,885
Therapy [Member]
Segment gross profit:
Segment gross profit	1,654	798	4,751	2,665
Segment operating income (loss):
Segment operating income (loss)	(173)	(711)	(735)	(2,149)
Therapy [Member] | Service [Member]
Segment revenues:
Total Revenue	$ 3,353	$ 1,838	$ 9,315	$ 5,362